Reata Pharmaceuticals Inc (NASDAQ:RETA) Director Cpmg Inc purchased 200,000 shares of Reata Pharmaceuticals stock in a transaction on Thursday, December 14th. The stock was bought at an average price of $24.79 per share, with a total value of $4,958,000.00. Following the transaction, the director now owns 113 shares of the company’s stock, valued at $2,801.27. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Reata Pharmaceuticals Inc (NASDAQ RETA) opened at $25.10 on Monday. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of -0.15. Reata Pharmaceuticals Inc has a 1 year low of $19.48 and a 1 year high of $40.88.
Reata Pharmaceuticals (NASDAQ:RETA) last released its earnings results on Monday, November 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.11). The company had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $12.54 million. Reata Pharmaceuticals’s revenue was up .0% on a year-over-year basis. equities analysts predict that Reata Pharmaceuticals Inc will post -1.91 earnings per share for the current fiscal year.
RETA has been the subject of a number of analyst reports. Cowen restated a “buy” rating on shares of Reata Pharmaceuticals in a research report on Tuesday, November 14th. ValuEngine cut Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Jefferies Group initiated coverage on Reata Pharmaceuticals in a research report on Wednesday, August 30th. They set a “buy” rating and a $44.00 target price for the company. Zacks Investment Research cut Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Finally, Robert W. Baird reiterated a “buy” rating and set a $47.00 target price on shares of Reata Pharmaceuticals in a research report on Friday, September 1st. Three analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $54.71.
ILLEGAL ACTIVITY WARNING: “Reata Pharmaceuticals Inc (RETA) Director Acquires $4,958,000.00 in Stock” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/12/18/reata-pharmaceuticals-inc-reta-director-acquires-4958000-00-in-stock.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.